GMNN and cancer: More specifically, the subgroup of patients exhibiting geminin immunoexpression in 1 − 4% of cancer cells showed a significantly worse outcome (HR 3.1, p = 0.01, CI 1.2–7.6) than the subgroup expressing geminin in ≥ 5% of cancer cells (Fig. 2).